A Thorough EKG Safety Study of TA-1790 (Avanafil)
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00769041
- Locations
- 🇺🇸
Covance Phase 1 Clinical Unit, Madison, Wisconsin, United States
A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00768404
- Locations
- 🇺🇸
Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00768209
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00745251
- Locations
- 🇺🇸
Kentucky Research Group, Louisville, Kentucky, United States
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
- First Posted Date
- 2008-08-19
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 101
- Registration Number
- NCT00737633
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults
- Conditions
- Diabetes
- Interventions
- Drug: Phentermine/TopiramateDrug: Placebo
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 130
- Registration Number
- NCT00600067
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 756
- Registration Number
- NCT00563368
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults
- Conditions
- Obesity
- Interventions
- Drug: Placebo matched phentermine/topiramate
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 1267
- Registration Number
- NCT00554216
- Locations
- 🇺🇸
Research, Ridgefield, Connecticut, United States
🇺🇸Research Site, Austin, Texas, United States
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 2487
- Registration Number
- NCT00553787
- Locations
- 🇺🇸
Research Site, Austin, Texas, United States
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 64
- Registration Number
- NCT00518466
- Locations
- 🇺🇸
VIVUS, Inc., Mountain View, California, United States